Up to 20% of patients with Parkinson disease (PD) report a positive family history,^[@R1]^ and genetic risk factors are more common in these families.^[@R2]^ Identification of specific genetic risk factors can reveal prognostic information, such as risk of cognitive impairment and/or rate of progression, and may soon highlight eligibility for personalized therapies.^[@R3]^ In addition, discovery of risk variants may inform genetic counseling of unaffected family members. Indeed, surveys of patients with PD and caregivers reveal a high level of interest in genetic testing for PD.^[@R4]^

More than 40 different loci that increase PD susceptibility have been identified in familial and sporadic PD.^[@R5],[@R6]^ Exome sequencing (ES) is ideally suited to identify single nucleotide variants (SNVs) in genetically heterogeneous diseases. In a study of adult patients referred for diverse clinical indications, ES had a diagnostic yield of 10% in individuals older than 30 years.^[@R7]^ In a recent study of 80 early-onset sporadic PD cases, ES yielded an overall diagnostic rate of 11%, with *GBA* alleles accounting for 5%.^[@R8]^ Nevertheless, clinical genetic testing is not routinely performed for PD, and ES remains poorly studied as a potential genetic diagnostic tool.

Although most identified PD risk alleles are SNVs, chromosomal structural rearrangements, or copy number variants (CNVs), also play an important role.^[@R9]^ Despite notable recent advances,^[@R10]^ ES remains insensitive for detection of small CNVs (\<50 kb).^[@R11]^ Several complementary approaches, including multiplex ligation-dependent probe amplification, bacterial artificial chromosome arrays, and single nucleotide polymorphism arrays,^[@R12],[@R13]^ have shown mixed success for identification of CNVs in PD cohorts. In contrast, genome-wide array-based comparative genomic hybridization (aCGH) is a highly-validated, sensitive clinical screening tool for CNV detection, offering exon-by-exon coverage for a multitude of disease-associated genes.^[@R14],[@R15]^ Although not yet adopted in most diagnostic laboratories, droplet digital PCR (ddPCR) is also emerging as a rapid and cost-efficient, targeted approach for the assessment of small CNVs at specific loci. Compared with standard quantitative PCR, digital PCR offers enhanced copy number and gene dosage sensitivity, precision, and reliability due to sample partitioning.^[@R16]^ In addition, mechanisms of CNV formation in PD remain understudied.

To our knowledge, integrated ES and aCGH for analysis of SNVs and CNVs, respectively, have not previously been systematically used in PD. We hypothesized that ES and aCGH in combination will yield an increased genetic molecular diagnostic rate. We also evaluated ddPCR as a novel strategy for confirmation of pathogenic CNVs in PD, and using breakpoint sequencing, we investigated potential mechanisms for CNV formation.

Methods {#s1}
=======

See supplementary information ([links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)) for complete methods, including further details and references.

Subjects {#s1-1}
--------

We studied 110 PD cases evaluated in the Baylor College of Medicine (BCM) PD Center and Movement Disorders Clinic in Houston, TX, with a family history of PD. As a positive control for aCGH, we included a sample from a known subject with an *SNCA* triplication.^[@R17][@R18][@R19]^ We also interrogated a Baylor Genetics diagnostic laboratory sample including 12,922 clinical referral samples for aCGH from peripheral blood using either v9 or v10 Baylor arrays. Subject numbers throughout the text are consistent with clinical and demographic details provided in table e-1 ([links.lww.com/NXG/A306](http://links.lww.com/NXG/A306)).

Standard protocol approvals, registrations, and subject consents {#s1-2}
----------------------------------------------------------------

All subjects provided informed consent. The BCM Institutional Review Board approved this study along with the analysis of aggregate clinical genomic data.

Gene set definition and variant criteria {#s1-3}
----------------------------------------

We focused our analyses on genes and variants established to cause familial PD, including the autosomal dominant loci, *SNCA* (*PARK1*, MIM\#168601), *GBA* (MIM\#168600), *LRRK2* (MIM\#607060), *GCH1* (MIM\#600225), *DNAJC13* (MIM\#616361), and *VPS35* (MIM\#614203), as well as the autosomal recessive loci, *PRKN* (*PARK2*, MIM\#600116), *PINK1* (MIM\#605909) and *PARK7* (*DJ1*, MIM\#606324), based on the available literature in April 2015 when this study was initiated.^[@R5],[@R6]^ In our CNV analyses, we also considered deletions at 22q11.2. Gene names in this study conform to current guidelines from the HUGO Gene Nomenclature Committee ([genenames.org](https://www.genenames.org/)). All pathogenic alleles included in this study are well-established, nonsynonymous coding variants with moderate to high penetrance (odds ratio \[OR\] \>2) meeting stringent evidence for replication across studies or within the same study. We considered all other variants discovered in these genes but not previously reported in PD to be variants of unknown significance (VUSs).

Detection and confirmation of SNVs and CNVs {#s1-4}
-------------------------------------------

We extracted genomic DNA from peripheral blood samples obtained from each participant and performed ES using the Illumina HiSeq 2000 at the BCM Human Genome Sequencing Center. Samples achieved an average of 95% of targeted exome bases covered to a depth of 20X or greater. All pathogenic SNVs detected were confirmed via Sanger sequencing. Genome-wide array CGH was performed on 99 of 110 subjects for which sufficient DNA remained using Baylor Genetics v10 2x400K clinical-grade oligonucleotide microarrays. We defined potential CNVs as those regions with 3 or more consecutive probes with consistent direction of effect. For confirmation, we used a custom 8x60K high-density array through Agilent (Santa Clara, CA). To confirm CNVs at *PRKN* and *GBA*, we additionally performed ddPCR (see e-Methods for detailed protocol, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)).

Data availability {#s1-5}
-----------------

For all subjects in the BCM cohort who consented to allow for public data sharing, ES and aCGH are in process for release in relevant genomic databases. The complete ES and aCGH data sets are also available on request by contacting the corresponding author, Dr. Shulman (<joshua.shulman@bcm.edu>).

Results {#s2}
=======

We pursued genetic diagnostic evaluation of 110 total subjects (including 109 unrelated probands) with familial PD. The mean age at onset was 50 years (SD = 15); 51% were male. The ethnic composition of the cohort was 72% Caucasian, 17% Hispanic, 6% East Asian, South Asian or Middle Eastern, and 6% undefined (not reported).

Single nucleotide variants {#s2-1}
--------------------------

We first examined subject ES data for pathogenic SNVs in established PD genes (see Methods). Among the dominant PD loci, 15 individuals had variants in *LRRK2* (c.6055G\>A:p.Gly2019Ser and c.4321C\>G:p.Arg1441Gly) and *GBA* (c.1093G\>A:p.Glu365Lys, c.1223C\>T:p.Thr408Met, c.1448T\>C:p.Leu483Pro, and c.1226A\>G:p.Asn409Ser) ([table 1](#T1){ref-type="table"} and table e-1, [links.lww.com/NXG/A306](http://links.lww.com/NXG/A306)). Two subjects each harbored heterozygous SNVs in both *GBA* and *LRRK2*, i.e., were double heterozygotes. One such subject had a combination of *LRRK2* p.Gly2019Ser and *GBA* p.Glu365Lys (subject 2), whereas the other had *LRRK2* p.Gly2019Ser and *GBA* p.Leu483Pro (subject 13). Both subjects had onset of PD symptoms in their 40s. On initial examination, subject 2 had tremor at rest, rigidity, bradykinesia, and dystonic posturing in both hands. She reported a history of PD in her father and paternal grandfather (figure e-1A, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305), and table e-1, [links.lww.com/NXG/A306](http://links.lww.com/NXG/A306)). There was no history of cognitive impairment or dementia. Subject 13 presented with resting tremor, rigidity, and bradykinesia. She reported a family history of PD in her paternal uncle (figure e-1B, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305), and table e-1, [links.lww.com/NXG/A306](http://links.lww.com/NXG/A306)). Ten years after PD diagnosis, she developed visual hallucinations and delusions. The subjects were of European and Hispanic ancestry, respectively; neither reported Ashkenazi Jewish heritage.

###### 

SNVs associated with increased PD risk detected via exome sequencing
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ES also revealed 7 individuals with pathogenic variants in loci usually associated with autosomal recessive PD, including *PRKN* (6 individuals) and *PARK7* (1 individual). However, all subjects were heterozygous SNV carriers, and therefore, isolated ES was nondiagnostic ([table 1](#T1){ref-type="table"}). Therefore, based on ES alone, we identified a pathogenic variant accounting for PD in 13.8% (n = 15 of 109 probands) of our familial PD cohort. We confirmed all implicated variants via Sanger sequencing. Besides the pathogenic variants noted above, ES also identified heterozygous VUSs in many PD risk genes (table e-2, [links.lww.com/NXG/A306](http://links.lww.com/NXG/A306)).

Copy number variants {#s2-2}
--------------------

We next interrogated aCGH data for pathogenic CNVs among PD genes. Our analyses included 99 of 110 total subjects evaluated by ES. We did not detect any CNVs in *VPS35*, *LRRK2*, *DNAJC13*, *GCH1*, *PARK7*, or *PINK1*, nor did we identify any candidate deletions at the 22q11.2 locus. However, we discovered CNVs in *SNCA* (n = 1), *GBA* (n = 1), and *PRKN* (n = 5). We confirmed all reported CNVs through custom high-density arrays and breakpoint sequencing. CNVs in *SNCA* and *GBA* affect dominant PD genes and were therefore diagnostic based on aCGH alone. We consider all heterozygous CNVs in the recessive PD gene, *PRKN*, in combination with ES results (see next section). Overall, isolated aCGH identified a diagnostic genetic risk factor for PD in 2.0% of our cohort (n = 2 of 99 probands). Based on aCGH, we also detected numerous large CNVs (\>1 Mb) within our cohort that affect other genomic loci; these variants remain of uncertain clinical significance (table e-3, [links.lww.com/NXG/A306](http://links.lww.com/NXG/A306)).

In subject 3, we detected a 248-kb duplication encompassing *SNCA*, as well as the adjacent gene, *MMRN1*. We confirmed this CNV by high-density aCGH and breakpoint analysis ([figure 1A](#F1){ref-type="fig"}). On initial examination, this subject exhibited rigidity, tremor, and gait impairment, along with hyperreflexia and clonus. The subject was of Hispanic and Native American ancestry; the subject\'s father had PD with dementia. Besides providing independent confirmation, breakpoint sequencing can provide clues to mechanisms of CNV formation. In the case of subject 3, we identified a 1-bp microhomology domain, which is a short sequence that is identical to another region in the genome reduced from 2 copies to 1 during the template switch accompanying replicative repair.^[@R20]^ Microhomology is characteristic of certain DNA replication errors that can generate CNVs (see Discussion).^[@R21],[@R22]^ As a positive control for our aCGH analysis, we also included a known *SNCA* triplication sample from the index family in which *SNCA* locus multiplication was first discovered as a cause for PD.^[@R17][@R18][@R19]^ Breakpoint sequencing revealed that this copy number alteration is a 1.7-Mb complex genomic rearrangement ([figure 1B](#F1){ref-type="fig"}), consisting of a duplication-inverted triplication-duplication (DUP-TRP/INV-DUP). This finding confirms and extends prior investigation of this particular structural variant^[@R23]^ and is also consistent with a likely replication-based mechanism for CNV formation.^[@R24]^

![aCGH plots and breakpoint junction sequences of 2 CNVs involving *SNCA*\
(A) In subject 3, a 248-kb duplication was identified. In this case, the whole *SNCA* gene was duplicated. The junction sequence (bottom) is aligned with upstream and downstream reference sequences, with the blue and pink colors indicating their different origins and the red indicating inserted nucleotides and microhomology. (B) A 1.7-Mb DUP-TRP/INV-DUP rearrangement was identified in the index subject with a known *SNCA* multiplication.^[@R17][@R18][@R19]^ The x-axis indicates the chromosomal regions surrounding *SNCA*. The y-axis indicates the subject vs control log~2~ ratio of the aCGH results, with duplications at 0.58, triplications at 1, and heterozygous deletions at −1 based on theoretical calculations. Red dots in the graph represent probes with log~2~ ratio \>0.25, black dots with log~2~ ratio from 0.25 to −0.25, and green dots with log~2~ ratio \<−0.25. The normal-duplication-triplication transition regions are magnified in boxes above the plot. The entire *SNCA* gene is triplicated. In addition, an SNP (rs12651181, underlined) was detected close to JCT2. aCGH = array-based comparative genomic hybridization; CNV = copy number variant; DUP-TRP/INV-DUP; duplication-triplication inverted-duplication; SNP = single nucleotide polymorphism.](NG2019012831f1){#F1}

We also discovered a heterozygous intragenic deletion in *GBA* in 1 subject ([figure 2](#F2){ref-type="fig"}), who presented at age 28 years with tremor, bradykinesia, and rigidity. She had an excellent response to levodopa in her early 30s and subsequently developed dyskinesia. The subject was of European descent, and both of her maternal grandparents were also diagnosed with PD (figure e-1C, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)). Because variant confirmation at the *GBA* locus can be complicated by an adjacent pseudogene with significant homology, we confirmed the 4.7-kb deletion of exons 2--8 using long-range PCR. Using breakpoint sequencing, we also confirmed heterozygosity and further revealed a 5-bp microhomology domain consistent with CNV formation due to nonhomologous recombination or replication errors ([figure 2B](#F2){ref-type="fig"}).

![aCGH plot and breakpoint junction sequence of *GBA* deletion\
(A) aCGH plot and (B) junction sequence of a 4.7-kb deletion identified involving *GBA* in subject 1. The deletion (shadowed) encompasses 7 exons of *GBA* (from exon 2 to exon 8). (C) By agarose gel electrophoresis, the amplification of the deleted region (Del) in subject 1 showed a ∼5 kb discrepancy compared with a control (Ctl), consistent with aCGH findings. PCR showed preferential amplification of the shorter fragment in the Del lane. aCGH = array-based comparative genomic hybridization.](NG2019012831f2){#F2}

Integrated analysis of SNVs and CNVs {#s2-3}
------------------------------------

As highlighted above, isolated ES and aCGH each identified a number of subjects with heterozygous SNVs or CNVs affecting recessive genes. To determine whether these changes might be diagnostic, we next examined the results together for potential biallelic variation due to both an SNV allele and a CNV allele. Indeed, 3 subjects in our cohort were newly identified as potential compound heterozygous carriers of both a pathogenic CNV and SNV in *PRKN* ([figure 3](#F3){ref-type="fig"}). Subject 6 had a 364-kb duplication of exons 4--6 and a frameshift deletion c.155delA:p.Asn52Metfs\*29. Subject 20 had a 222-kb deletion of exons 8 and 9 and a stopgain c.1358G\>A:p.Trp453\*. Subject 11 harbored a pathogenic *PRKN* SNV (c.1310C\>T:p.Pro437Leu) and a complex locus rearrangement, including a copy number neutral region flanked by 404 kb and 199 kb duplications affecting exons 2 and 3 and exons 5 and 6, respectively ([figure 3B](#F3){ref-type="fig"}). Our cohort also included 2 brothers with known *PRKN*-PD^[@R25]^; however, neither ES nor aCGH was previously performed on these subjects. Our analysis confirmed compound heterozygosity for the known pathogenic SNV in exon 6 (c.719C\>T:p.Thr240Met, apparently homozygous on ES) and a CNV (178-kb deletion of exons 5 and 6) ([figure 3C](#F3){ref-type="fig"}). Of interest, ES also discovered an additional VUS (c.2T\>C:p.Met1Thr). Based on available clinical information (table e-1, [links.lww.com/NXG/A306](http://links.lww.com/NXG/A306)), all subjects with *PRKN* variants had young-onset PD (age range 15--36 years).

![aCGH plots and breakpoint junction sequences of *PRKN* CNVs\
aCGH plots (left panel) and breakpoint junction sequences (right panel) of CNVs identified involving the *PRKN* gene in the cohort. At the top, a schematic gene structure demonstrates the 12 exons of *PRKN*. (A) In subject 20, a 222-kb deletion covering exons 8 and 9 was accompanied by a known pathogenic nonsense mutation c.1358G\>A:p.Trp453\* (gnomAD frequency = 0) in exon 12. (B) In subject 11, in addition to a missense variant c.1310C\>T:p.Pro437Leu (exon 12), a duplication-normal-duplication (DUP-NML-DUP) was identified. (C) Siblings 21 and 22 share a pathogenic missense variant c.719C\>T:p.Thr240Met (in exon 6) and a 178-kb deletion (disrupting exons 5 and 6). (D) In subject 6, a 364-kb duplication encompassed exons 4 to 6. A known pathogenic frameshift variant c.155delA:p.Asn52Metfs\*29 was identified in exon 2 (gnomAD frequency = 2.5 × 10^−4^). Breakpoint sequencing was not successful in this sample. aCGH = array-based comparative genomic hybridization; CNV = copy number variant; gnomAD = Genome Aggregation Database.](NG2019012831f3){#F3}

We again confirmed all CNVs using custom, high-density arrays as well as breakpoint sequencing. In the case of subject 6, we were unable to successfully amplify breakpoint junctions despite multiple attempts, suggesting a more complex genomic rearrangement or raising the possibility that this duplication is located elsewhere in the genome. For all other *PRKN* CNVs, [figure 3](#F3){ref-type="fig"} shows the junction structures, highlighting likely mechanisms of CNV formation. Overall, integrated ES and CNV identified a genetic cause for PD in 4 additional probands, increasing the overall genetic diagnostic yield to 19.3% (n = 21).

Digital droplet PCR {#s2-4}
-------------------

Given the observed high frequency of *PRKN* CNVs in this familial PD cohort (∼5%), and the high cost of clinical-grade aCGH, we examined the feasibility of an exon-by-exon ddPCR assay to detect *PRKN* CNVs as a proof of principle. ddPCR is an emerging cost-effective method for sensitive and reliable assessment of specific CNVs. Indeed, ddPCR revealed all *PRKN* CNVs detected using aCGH (subjects 6, 11, 20, 21, and 22) ([figure 4A](#F4){ref-type="fig"}). We also interrogated an additional 92 cases from our cohort with available DNA for intragenic *PRKN* CNVs using ddPCR, without discovery of additional CNVs ([figure 4A](#F4){ref-type="fig"} and figure e-2, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)). We also applied ddPCR to screen for potential CNVs at the *GBA* locus. The 12-exon *GBA* shares high homology with the nearby 13-exon pseudogene, *GBAP1* ([figure 4B](#F4){ref-type="fig"}). As shown in [figure 4C](#F4){ref-type="fig"}, using ddPCR, we successfully amplified all 12 exons of *GBA*. Six exons (1, 2, 4, 7, 9, and 10) identified unique amplicons with a positive droplet ratio of 1, whereas the other 6 exons (3, 5, 6, 8, 11, and 12) demonstrated shared amplicons with the pseudogene, resulting in a droplet ratio of 2. Importantly, ddPCR also confirmed the deletion of *GBA* exons 2--8 in subject 1 ([figure 4C](#F4){ref-type="fig"}) and did not reveal evidence for additional CNVs in 85 other samples tested ([figure 4C](#F4){ref-type="fig"} and figure e-3, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)). Of note, ddPCR initially suggested a single exon deletion (exon 6) in subject 48; however, further investigation using Sanger sequencing revealed an intronic SNV likely degrading ddPCR amplification (figure e-4, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)). We redesigned the affected primer and demonstrated full amplification of exon 6 (e-Methods and figure e-4, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)). Overall, our results suggest that ddPCR may be a sensitive and specific diagnostic tool for CNV detection in PD, including at loci such as *GBA* complicated by genomic regions with high sequence homology.

![*PRKN* and *GBA* ddPCR results of representative subjects\
(A) Positive droplet concentrations in 8 subjects. Primer pairs for the 12 exons of *PRKN* and 2 control genes, *RPPH1* and *TERT*, were used to obtain positive droplet concentrations from PCR in each individual (e-Methods and figure e-4A, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)). The y-axis shows exon-by-exon results in 13 columns with different colors, showing comparable results to the average value of *RPPH1* and *TERT*. A y-axis value of 0.5 indicates a deletion, 1 copy neutral (no deletion, no duplication), and 1.5 a duplication. In subject 6, a duplication involving exons 4 to 6 was identified as shown by aCGH; in subject 11, exons 2, 4, 5, and 6 demonstrated copy number gains; in subject 20, there is a copy number loss involving exons 8 and 9; similarly, in subjects 21 and 22 a copy number loss of exons 5 and 6 is detected. In subjects 1, 23, and HapMap NA10851, no amplicons showed altered copy number. See also figure e-2 ([links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)). Copy number variants are denoted with asterisks (\*). (B) *GBA* and its nearby pseudogene, *GBAP1*, share a high degree of sequence homology, with ddPCR primer pairs for 6 of the 12 exons of *GBA* producing amplicons concurrently from *GBA* and *GBAP1*. *GBA* exons 3, 5, 6, 8, 11, and 12 are color coded to demonstrate their homologous regions within *GBAP1*, which result in a doubling of the apparent copy number identified by ddPCR: 4 instead of 2 copies (ratio = 2), indicate copy number neutrality for these exons. *GBA* exon 5 is homologous with an intragenic region between exons 4 and 5 of *GBAP1*. (C) ddPCR detected potential exonic CNVs in *GBA*. Here, we demonstrate a deletion identified in subject 1, compared with HapMap subject NA10581 and other 2 subjects, ratios of exons 2 to 8 were each reduced by 0.5-fold, consistent with a deletion involving these exons. Deleted exons are denoted with an asterisk (\*); deleted exons with a droplet ratio of 1.5 due to *GBAP1* amplification are denoted with an arrowhead. See also figure e-3 ([links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)). aCGH = array-based comparative genomic hybridization; CNV = copy number variant; ddPCR = droplet digital PCR.](NG2019012831f4){#F4}

CNV burden in clinical cohorts {#s2-5}
------------------------------

Compared with SNVs, limited reference data are available on the population frequency of CNVs, especially in neurologically healthy adult samples, hampering the interpretation of CNV frequencies detected in our cohort. We therefore leveraged data from the Baylor Genetics diagnostic laboratory, including 12,922 aCGH clinical referral samples. This large cohort is skewed for pediatric cases (mean age = 7.4 years, SD = 9.7 years, range 0--79 years), reflecting the more common use of aCGH in this population. Although the cohort includes a substantial proportion of individuals with developmental delay, autism, and dysmorphic features, there were no recorded submissions for PD. Based on stringent criteria (see e-Methods, [links.lww.com/NXG/A305](http://links.lww.com/NXG/A305)), at most PD loci, CNVs were either absent (*DNAJC13*, *LRRK2*, *PINK1*, and *SNCA*) or very rare at *VPS35* (n = 2), *GCH1* (n = 1), and *PARK7* (n = 6, all subjects had 1p36 deletion syndrome). By contrast, CNVs were more common at 22q11.2 (n = 90, all losses affecting the critical region) and *PRKN* (n = 95). Notably, the frequency of *PRKN* CNVs in our PD cohort (5.1%) represents a significant increase when compared with that of the Baylor Genetics clinical reference sample (frequency = 0.74%, OR = 7.2, 95% confidence interval 2.9--18.1, *p* = 2.8 × 10^−5^). Because of the pseudogene, *GBAP1*, and suboptimal probe coverage, the array does not reliably capture *GBA* CNVs.

Discussion {#s3}
==========

Establishing a specific genetic diagnosis can provide information about PD risk and progression relevant to patients and their families and may soon influence treatment decisions.^[@R26]^ In our familial PD sample, ES and aCGH independently identified a genetic cause for PD in 13.8% and 2.0%, respectively. The diagnostic yield for ES was slightly higher than that recently reported for an early-onset PD cohort (11.25%)^[@R8]^ and was also greater than the 10.7% diagnostic rate in an unselected adult series referred for clinical diagnostic ES.^[@R7]^ Given incipient treatment trials for *GBA-PD* and the potential importance of identifying eligible subjects in the future,^[@R26]^ our analyses considered lower-risk pathogenic alleles (OR ∼2.4),^[@R27]^ p.Glu365Lys and p.Thr408Met, along with higher-penetrance variants (e.g., p.Leu483Pro, OR \>5).^[@R28]^ Importantly, integrated ES and aCGH identified 5 additional subjects (4 unrelated probands)---including a subject with a *GBA* deletion---yielding an overall combined diagnostic rate of 19.3%. We also uncovered numerous VUS, including SNVs within Mendelian PD genes (table e-2, [links.lww.com/NXG/A306](http://links.lww.com/NXG/A306)) as well as large CNVs affecting other loci (table e-4, [links.lww.com/NXG/A306](http://links.lww.com/NXG/A306)). Although additional evidence will be required to confirm or refute pathogenicity, our genetic diagnostic rate would nearly double if these VUS in PD genes are bona fide risk factors. Overall, our findings suggest that integrated ES and aCGH analysis is essential for routine, high-confidence genetic diagnosis in familial PD.

Most genetic diagnostic studies in PD cohorts to date have ignored the potential contribution of CNVs. Similarly, except in several notable targeted CNV studies,^[@R12],[@R29]^ research-based PD gene discovery has almost exclusively focused on SNVs, using ES or genotyping arrays. Importantly, we would have missed multiple pathogenic CNV alleles at both autosomal dominant (*SNCA* and *GBA*) and recessive (*PRKN*) loci without performing aCGH. In 5 subjects, pathogenic alleles discovered at *PRKN* would have been nondiagnostic based on isolated ES, leading to misclassification as heterozygous carriers, whereas integrated SNV-CNV analyses successfully established the molecular diagnosis of *PRKN*-PD. Our findings suggest caution for interpretation of studies attributing PD risk to either *PRKN* CNV or SNV heterozygous carrier states in isolation, consistent with prior studies.^[@R30]^ Although we did not detect any CNVs at *PINK1* or *PARK7* in our cohort, the importance of integrated SNV-CNV analysis may extend to other autosomal recessive PD loci besides *PRKN*. Because our CNV and SNV data are unphased, and parental genotypes are not available, we cannot definitively exclude the possibility that certain CNVs and SNVs at *PRKN* were in cis- rather than trans-configuration. Nevertheless, our data suggest that structural variants may co-occur with SNVs more commonly than previously recognized, making consideration of both allele types important for comprehensive genetic diagnosis in PD.

ES has significantly accelerated the scope of gene discovery in PD and other neurologic disorders, but remains insensitive to allele classes such as trinucleotide repeat expansions and CNVs. Although bioinformatic tools may help identify CNVs from ES data, available algorithms have high false-positive rates when compared with aCGH,^[@R31]^ and this method may miss up to 30% of clinically relevant CNVs.^[@R11]^ To our knowledge, genome-wide aCGH with exon-by-exon coverage has not been previously applied in PD. Limitations of aCGH include significant cost and the possibility of missing small deletions/duplications. Alternative methods, such as ddPCR, may offer a cost-effective alternative for screening specific genes,^[@R32]^ including for small CNVs. In our study, ddPCR showed high sensitivity and specificity for detection of CNVs at both *PRKN* and *GBA*. Moreover, ddPCR successfully differentiated copy number changes affecting exons unique to *GBA* avoiding potential confounding by the adjacent pseudogene, *GBAP1*.

Despite evidence of an important role in disease risk, the mechanism(s) for generating CNVs relevant to PD remain largely unknown. Broadly, CNVs may form through mechanisms associated with DNA recombination, DNA replication, and/or DNA repair.^[@R20]^ Nonallelic homologous recombination can result in recurrent rearrangements. In contrast, nonhomologous end joining,^[@R20]^ fork stalling and template switching (FoSTeS) and microhomology-mediated break-induced replication (MMBIR),^[@R21]^ lead to nonrecurrent CNVs. In our study, all junction breakpoint sequencing results were consistent with the FoSTeS/MMBIR mechanism, including for CNV alleles discovered at *SNCA*, *PRKN*, and *GBA*. These results are consistent with a recent analysis of *SNCA* duplications from 6 independent cases.^[@R33]^ These findings have important implications for screening assays because the detection of nonrecurrent CNVs requires methods sensitive for heterogeneous, exon-by-exon changes. The FoSTeS/MMBIR mechanism can also trigger multiple iterative template switches in a single event, leading to the generation of more complex genomic rearrangements. Breakpoint sequencing of an *SNCA* CNV first observed in the Spellman-Muenter/Iowa kindred^[@R18],[@R19]^ confirmed the DUP-TRP-DUP structure^[@R23]^ and further revealed an internal inversion (DUP-TRP/INV-DUP) and microhomology. This rearrangement must have arisen during mitosis via FoSTeS/MMBIR^[@R20]^ and therefore likely represents a de novo triplication, in contrast to the meiotic *PMP22* triplications observed in Charcot-Marie-Tooth (MIM\#118220), which derives from a duplication in the previous generation.^[@R34]^ Our results therefore demonstrate the essential role of breakpoint junction sequencing in definitively resolving CNV structure and responsible mechanisms.

Deletions in *GBA* rarely contribute to autosomal recessive Gaucher disease (MIM\#230800).^[@R35]^ Our discovery of a *GBA* deletion allele in a subject with PD, expected to cause glucocerobrosidase haploinsufficiency, adds to other emerging evidence supporting a loss-of-function mechanism in *GBA*-PD.^[@R36]^ It will be informative to screen for additional *GBA* CNVs in additional case/control cohorts---perhaps using ddPCR---to determine how commonly these alleles are associated with PD risk and estimate their effect size and penetrance. We also identified 2 subjects doubly heterozygous for SNVs in both *GBA* and *LRRK2*, consistent with prior reports.^[@R37]^ We expect that additional PD cases compatible with oligogenic inheritance models will emerge following widespread adoption of comprehensive, genome-wide diagnostic approaches, including ES and aCGH. Future studies must address how such alleles may interact to modify PD risk and/or clinical manifestations. Finally, although our study focused on pathogenic alleles in established Mendelian loci, future assessment of a more complete spectrum of genetic variation through integrated SNV-CNV analysis is also likely to enhance power for novel PD gene discovery.
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